Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $20.00 target price on the stock.

Poseida Therapeutics Stock Up 0.7 %

Shares of Poseida Therapeutics stock traded up $0.02 during trading on Thursday, reaching $2.79. The stock had a trading volume of 1,355,737 shares, compared to its average volume of 722,879. The company has a market capitalization of $270.43 million, a price-to-earnings ratio of -2.01 and a beta of 0.46. The stock has a fifty day moving average price of $2.97 and a two-hundred day moving average price of $2.94. Poseida Therapeutics has a 52 week low of $1.54 and a 52 week high of $4.27. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 0.56.

Poseida Therapeutics (NASDAQ:PSTX - Get Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.09. Poseida Therapeutics had a negative return on equity of 94.90% and a negative net margin of 190.76%. The business had revenue of $25.00 million for the quarter, compared to analyst estimates of $12.50 million. Sell-side analysts predict that Poseida Therapeutics will post -1.77 EPS for the current fiscal year.

Institutional Trading of Poseida Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Silverarc Capital Management LLC raised its stake in Poseida Therapeutics by 21.1% in the third quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company's stock valued at $8,492,000 after buying an additional 622,037 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Poseida Therapeutics by 186.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 342,857 shares of the company's stock valued at $816,000 after buying an additional 223,280 shares during the period. MCF Advisors LLC raised its stake in Poseida Therapeutics by 476.4% in the fourth quarter. MCF Advisors LLC now owns 247,024 shares of the company's stock valued at $830,000 after buying an additional 204,170 shares during the period. Blair William & Co. IL raised its stake in Poseida Therapeutics by 30.2% in the third quarter. Blair William & Co. IL now owns 740,650 shares of the company's stock valued at $1,763,000 after buying an additional 171,910 shares during the period. Finally, Cantor Fitzgerald L. P. bought a new stake in Poseida Therapeutics in the fourth quarter valued at approximately $169,000. Institutional investors own 46.87% of the company's stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.